Daiichi Sankyo enters research collaboration for COVID-19

BioSpectrum Asia|July 2020

We're offering this story for free to read so that you can stay updated on the COVID-19 outbreak
Daiichi Sankyo enters research collaboration for COVID-19
The University of Tokyo, RIKEN, Nichi-Iko Pharmaceutical and Daiichi Sankyo in Japan have reached a basic agreement on collaborative R&D on a Nafamostat inhalation formulation for the treatment of novel coronavirus infection.
articleRead

You can read up to 3 premium stories before you subscribe to Magzter GOLD

Log in, if you are already a subscriber

GoldLogo

Get unlimited access to thousands of curated premium stories and 5,000+ magazines

READ THE ENTIRE ISSUE

July 2020